Ryvu Therapeutics
- Biotech or pharma, therapeutic R&D
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel oncology therapies that address emerging targets in oncology. Internally discovered pipeline candidates at Ryvu use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology and includes small molecules and antibody-drug conjugates. Ryvu’s most advanced program is RVU120, a selective CDK8/19 kinase inhibitor that is currently in Phase II development AML, MDS, and myelofibrosis. Ryvu’s next wholly owned asset is RVU305, a potentially best-in-class, brain-permeable PRMT5 inhibitor that is targeting completion of IND/CTA-enabling studies in 2H25. Ryvu is also advancing two novel discovery platforms: a) novel ADC payloads, including immunocytotoxic and synthetic lethal mechanisms, and b) ONCO Prime, which is using patient-derived cells and engineered models to discover new precision oncology targets.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}